Regulatory approval
Published by the Health Service Executive.
The Republic of Ireland's Health Service Executive (HSE) has approved quizartinib in combination with standard daunorubicin and cytarabine induction therapy for reimbursement as a treatment option for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) who are FLT3-ITD mutation positive.
This is written in the approval document as:
Quizartinib in combination with standard DAUNOrubicin and cytarabine induction chemotherapy for adult patients with newly diagnosed acute myeloid leukaemia (AML) who are FLT3-ITD mutation positive.
Citation
Therapeutic response
Precision oncology relationships for therapeutic response derived from this regulatory approval.
| Type | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| Sensitivity (+) | FLT3-ITD | Acute Myeloid Leukemia | Cytarabine, Daunorubicin, Quizartinib |